Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Mar 3;2015(3):220-1.
doi: 10.1093/omcr/omv015. eCollection 2015 Mar.

Etanercept-associated myelitis

Carsten Finke  1 , Wolf Schmidt  1 , Eberhard Siebert  2 , Florian Ostendorf  1
Affiliations
Case Reports

Etanercept-associated myelitis

Carsten Finke et al. Oxf Med Case Reports. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
(a) Sagittal T2-weighted MRI shows a single posterior hyperintense demyelinating lesion of the cord at T5-6. (b) Sagittal CE T1 shows contrast enhancement of the lesion indicative of blood-spinal cord barrier disruption. (c): On axial CE T1 the lesion is located dorsomedially and limited to the posterior columns.
See this image and copyright information in PMC

References

    1. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford). 2013;52:868–874. - PubMed
    1. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53:457–465. - PubMed
    1. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BME, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47:1531–1534. - PubMed
    1. Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17:1472–1487. - PubMed
    1. Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010;257:1421–1431. - PubMed

Publication types

LinkOut - more resources